Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PDE9A | O76083 | 3/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640045 | 0.87 | ALDH1A1 (0.58) | IDO1MAPK1PDE9ACLK1CLK2 | |
| SCHEMBL5618029 | 0.84 | MAPK1 (0.53) | MAPK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL5618530 | 0.81 | MAPK1 (0.59) | MAPK1PDE9APIM1PDE1CKDM4E | |
| SCHEMBL2639657 | 0.79 | IDO1 (0.43) | IDO1TDO2MAPK1CLK1CLK2 | |
| SCHEMBL3621355 | 0.79 | KCNA5 (0.46) | IDO1TDO2MAPK1KDM4EALDH1A1 | |
| SCHEMBL14916649 | 0.78 | PDE9A (0.70) | MAPK1PDE9ACLK2DYRK1ACLK4 | |
| SCHEMBL14916740 | 0.78 | PDE9A (0.65) | MAPK1PDE9APIM1PDE1CKDM4E | |
| SCHEMBL14916341 | 0.78 | PDE9A (0.49) | IDO1TDO2MAPK1PDE9ACLK2 | |
| SCHEMBL2168476 | 0.75 | KDM4E (0.57) | CLK1KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL10097329 | 0.74 | MAPK13 (0.61) | CLK1CLK2DYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667973-B1 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | claimed |
| JP-4794445-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | claimed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | claimed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1667973-B1 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078154-A1 | Quinoline potassium channel inhibitors | KCNQ2, KCNQ1, KCNJ2 | IDO1 2597/4885TDO2 3762/4885MAPK1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.